Healthia (ASX: HLA) is a holding company engaged in the operation and expansion of podiatry and physiotherapy clinics, and Business-to-Business businesses in Australia. It also intends in identifying, acquiring and integrating new clinics and organically growing its portfolio of clinics and other allied health businesses. It operates through the Physiotherapy and Podiatry segments. The Physiotherapy segment includes the extended rehabilitation clinics. The Podiatry segment covers iOrthotics and D.B.S. Medical.
The company delivered impressive growth in organic revenue and underlying earnings in comparison to the prior period. It reported underlying revenue of A$61.5 million, representing a growth of 39% and the organic revenue growth stood at 14.5%.
Healthia shares were rather flat after the crash in March 2020. However, since November, the share price has been slowly climbing. Today’s 8% surge on the back of a positive result takes the shares to $1.76 at market close – demanding a market cap of $135 million. The performance in the last 6 months has been 87% and 36% in the year-to-date. This performance is better than most of the top ASX healthcare stocks during the period.
Growth stocks are potentially one of the hardest to pick as there are a lot of factors that need to be considered – from industry tailwinds to financial health of the individual stocks, and a lot of little things in between them. Shares in Value research team have picked their top 3 ASX stocks to buy in 2021. Click here to download the report for free.